TY - JOUR
T1 - CD38 a biomarker and therapeutic target in non-hematopoietic tumors
AU - Barrientos-Robledo, Susana G.
AU - Cebada-Ruiz, Jorge A.
AU - Rodríguez-Alba, Juan C.
AU - Baltierra-Uribe, Shantal L.
AU - Díaz Y Orea, Maria A.
AU - Romero-Ramírez, Héctor
N1 - Publisher Copyright:
© 2022 Future Medicine Ltd.
PY - 2022/4
Y1 - 2022/4
N2 - The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogenesis, cell invasion and progression of the disease. Thus, CD38 has been used as a progression marker for different cancer types as well as in immunotherapy. This review focuses on describing the involvement of CD38 in various non-hematopoietic cancers.
AB - The type II transmembrane glycoprotein CD38 has recently been implicated in regulating metabolism and the pathogenesis of multiple conditions, including aging, inflammation and cancer. CD38 is overexpressed in several tumor cells and microenvironment tumoral cells, associated to migration, angiogenesis, cell invasion and progression of the disease. Thus, CD38 has been used as a progression marker for different cancer types as well as in immunotherapy. This review focuses on describing the involvement of CD38 in various non-hematopoietic cancers.
KW - CD38
KW - angiogenesis
KW - cell invasion
KW - immunotherapy
KW - non-hematopoietic cancer
KW - tumor cells
UR - http://www.scopus.com/inward/record.url?scp=85127057323&partnerID=8YFLogxK
U2 - 10.2217/bmm-2021-0575
DO - 10.2217/bmm-2021-0575
M3 - Artículo de revisión
C2 - 35195042
AN - SCOPUS:85127057323
SN - 1752-0363
VL - 16
SP - 387
EP - 400
JO - Biomarkers in Medicine
JF - Biomarkers in Medicine
IS - 5
ER -
